Ken Griffin Pardes Biosciences, Inc. Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023
BUY
$1.4 - $1.95 $17,166 - $23,910
12,262 New
12,262 $22,000

Others Institutions Holding PRDS

# of Institutions
2
Shares Held
5.23M
Call Options Held
0
Put Options Held
0
View Full List

About PARDES BIOSCIENCES, INC.

PRDS Quotes by TradingView
  • Ticker PRDS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,320,900
  • Description
  • Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome ...
More about PRDS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email